Scheduling your presentation: A different approach to prednisone

Dear [Preferred Customer Name]:

Email Opener A

You are invited to a special presentation about a different approach to prednisone with RAYOS^® (prednisone) delayed—release tablets. RAYOS is approved for use in a variety of conditions, including rheumatoid arthritis, lupus(SLE), acute gouty arthritis, and polymyalgia rheumatica. You can consider delayed—release RAYOS for any patient for whom you would usually consider generic prednisone.

Email Opener B

Thank you for attending our speaker presentation. I'm glad you were able to join us to learn more about RAYOS^® (prednisone) delayed—release tablets. RAYOS is approved for use in a variety of conditions, including rheumatoid arthritis, lupus(SLE), acute gouty arthritis, and polymyalgia rheumatica. You can consider delayed—release RAYOS for any patient for whom you would usually consider generic prednisone.

Email Opener C

I'm sorry you weren't able to attend our speaker presentation. I wanted to take this opportunity to share some information with you about RAYOS^® (prednisone) delayed—release tablets. RAYOS is approved for use in a variety of conditions, including rheumatoid arthritis, lupus(SLE), acute gouty arthritis, and polymyalgia rheumatica. You can consider delayed—release RAYOS for any patient for whom you would usually consider generic prednisone.

Please refer to the Important Safety Information provided below.

Setup A

Please join us as we discuss clinical considerations for prescribing prednisone and evaluate the impact of circadian rhythms on disease activity.

Setup B

In case you want to review some key points of the presentation, here is some information that relates to what was discussed:

Setup C

I've attached a copy of the slides that were presented, as well as some key highlights from the presentation that you may want to consider:

Email Fragments(multi-optional)

Find out why it's

TIME FOR A DIFFERENT

APPROACH TO PREDNISONE.

Find out why it's time for a different approach to prednisone.

Get more information on

EVALUATING STRATEGIC TIMING OF

PREDNISONE DOSING IN RA.

Get more information on evaluating strategic
timing of prednisone dosing in RA.

Review the full presentation:

"Time for a Different

Approach to Prednisone"

REVIEW THE FULL PRESENTATION:
"Time for a Different Approach to Prednisone"

Find out how

RAYOS IMPROVED PRESPECIFIED

OUTCOMES IN CLINICAL TRIALS.

Find out how RAYOS improved prespecified outcomes in clinical trials.

Review how

RAYOS COINCIDES WITH

THE RISE OF CLINICAL SYMPTOMS.

Review how RAYOS coincides with the rise of clinical symptoms.

Review how

DELAYED RELEASE OFFERS

TIMELY DRUG EFFECTS.

Review how delayed release offers timely drug effects.

Please refer to the Important Safety Information provided below.

Closing A

In the meantime, if you have any questions about RAYOS for your patients with certain rheumatic conditions (as specified in the Prescribing Information) who may benefit from a delayed—release corticosteroid, please contact me via the email/phone provided below. I look forward to seeing you at our speaker presentation.

Closing B

I hope you will consider prescribing RAYOS for your patients with certain rheumatic conditions (as specified in the Prescribing Information) who may benefit from a delayed—release corticosteroid.

Please don't hesitate to reach out at any time if you have questions about RAYOS or any other Horizon Pharma product.

Closing C

I hope we can schedule a follow-up meeting to review the presentation.

In the meantime, you may want to consider whether any patients with certain rheumatic conditions (as specified in the Prescribing Information) in your practice could benefit from a corticosteroid with delayed—release technology. Please email or call me with any questions or to schedule a convenient time to meet.

Please refer to the Important Safety Information provided below.

Signoff Options

Sincerely,

Best regards,

Have a great day!

[Representative Name]

[Email Address]

[Phone]

RAYOS^® (prednisone) delayed—release tablets

INDICATIONS AND USAGE

RAYOS is a corticosteroid indicated:

As an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation
For the treatment of certain endocrine conditions
For palliation of certain neoplastic conditions

For a complete list of indications for RAYOS, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION ABOUT RAYOS

CONTRAINDICATIONS

Known hypersensitivity to prednisone or any excipients in the formulation

WARNINGS AND PRECAUTIONS

Corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome and hyperglycemia. Monitor patients for these conditions with chronic use. Taper doses gradually for withdrawal after chronic use
RAYOS may increase susceptibility to new infection and increase risk of exacerbation, dissemination or reactivation of latent infection. RAYOS may mask signs and symptoms of infection. The rate of infectious complications increases with increasing doses of corticosteroids
Corticosteroids can cause elevated blood pressure, salt and water retention and hypokalemia. Monitor blood pressure and sodium, potassium serum levels. RAYOS should be used with caution in patients with a history of recent myocardial infarction, congestive heart failure, hypertension or renal insufficiency
There is an increased risk of gastrointestinal (GI) perforation in patients with certain GI disorders. RAYOS may mask signs and symptoms of GI perforation
Corticosteroid use may be associated with behavioral and mood disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression and psychosis. Existing conditions may be aggravated
Corticosteroid use may lead to inhibition of bone growth in children and adolescents and the development of osteoporosis at any age. Give special consideration to patients at increased risk of osteoporosis (eg, postmenopausal women) before initiating corticosteroid therapy, and bone density should be monitored in patients on long-term corticosteroid therapy
Prolonged use of corticosteroids may result in cataracts, infections and glaucoma. Monitor intraocular pressure if corticosteroid therapy is continued for more than 6 weeks
Do not administer live or attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids
Long-term use of corticosteroids can have negative effects on growth and development in children. Monitor pediatric patients on long-term corticosteroid therapy
Fetal harm can occur with first trimester use of corticosteroids. Apprise women of potential harm to the fetus

ADVERSE REACTIONS

Common adverse reactions for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain

For a complete list of indications for RAYOS, please see the
full Prescribing Information.

For further information on RAYOS, please see the full Prescribing Information at www.RAYOSRX.com/PI.